Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan 16:13:9.
doi: 10.1186/s12916-014-0258-3.

Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial

Holger W Unger  1   2 , Maria Ome-Kaius  3 , Regina A Wangnapi  4 , Alexandra J Umbers  5   6 , Sarah Hanieh  7 , Connie S N Li Wai Suen  8 , Leanne J Robinson  9   10 , Anna Rosanas-Urgell  11   12 , Johanna Wapling  13 , Elvin Lufele  14 , Charles Kongs  15 , Paula Samol  16 , Desmond Sui  17 , Dupain Singirok  3 , Azucena Bardaji  18 , Louis Schofield  19   20 , Clara Menendez  21 , Inoni Betuela  22 , Peter Siba  23 , Ivo Mueller  24   25   26 , Stephen J Rogerson  27
Affiliations
Randomized Controlled Trial

Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial

Holger W Unger et al. BMC Med. .

Abstract

Background: Intermittent preventive treatment in pregnancy has not been evaluated outside of Africa. Low birthweight (LBW, <2,500 g) is common in Papua New Guinea (PNG) and contributing factors include malaria and reproductive tract infections.

Methods: From November 2009 to February 2013, we conducted a parallel group, randomised controlled trial in pregnant women (≤ 26 gestational weeks) in PNG. Sulphadoxine-pyrimethamine (1,500/75 mg) plus azithromycin (1 g twice daily for 2 days) (SPAZ) monthly from second trimester (intervention) was compared against sulphadoxine-pyrimethamine and chloroquine (450 to 600 mg, daily for three days) (SPCQ) given once, followed by SPCQ placebo (control). Women were assigned to treatment (1:1) using a randomisation sequence with block sizes of 32. Participants were blinded to assignments. The primary outcome was LBW. Analysis was by intention-to-treat.

Results: Of 2,793 women randomised, 2,021 (72.4%) were included in the primary outcome analysis (SPCQ: 1,008; SPAZ: 1,013). The prevalence of LBW was 15.1% (305/2,021). SPAZ reduced LBW (risk ratio [RR]: 0.74, 95% CI: 0.60-0.91, P = 0.005; absolute risk reduction (ARR): 4.5%, 95% CI: 1.4-7.6; number needed to treat: 22), and preterm delivery (0.62, 95% CI: 0.43-0.89, P = 0.010), and increased mean birthweight (41.9 g, 95% CI: 0.2-83.6, P = 0.049). SPAZ reduced maternal parasitaemia (RR: 0.57, 95% CI: 0.35-0.95, P = 0.029) and active placental malaria (0.68, 95% CI: 0.47-0.98, P = 0.037), and reduced carriage of gonorrhoea (0.66, 95% CI: 0.44-0.99, P = 0.041) at second visit. There were no treatment-related serious adverse events (SAEs), and the number of SAEs (intervention 13.1% [181/1,378], control 12.7% [174/1,374], P = 0.712) and AEs (intervention 10.5% [144/1,378], control 10.8% [149/1,374], P = 0.737) was similar. A major limitation of the study was the high loss to follow-up for birthweight.

Conclusions: SPAZ was efficacious and safe in reducing LBW, possibly acting through multiple mechanisms including the effect on malaria and on sexually transmitted infections. The efficacy of SPAZ in the presence of resistant parasites and the contribution of AZ to bacterial antibiotic resistance require further study. The ability of SPAZ to improve pregnancy outcomes warrants further evaluation.

Trial registration: ClinicalTrials.gov NCT01136850 (06 April 2010).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile. IPTp, Intermittent preventive treatment in pregnancy; SP, Sulphadoxine-pyrimethamine; CQ, Chloroquine; AZ, Azithromycin; ITT, Intention-to-treat analysis; PP, Per protocol analysis.
Figure 2
Figure 2
Detailed screening data for 279 clinic sessions (held at nine antenatal clinics) during which 860 of 2,793 trial participants (30.8% ) were recruited.
Figure 3
Figure 3
Cumulative frequency (a) and Kernel density plot (b) of birthweight, by trial arm (ITT analysis).
See this image and copyright information in PMC

References

    1. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 2004;17:760–9. doi: 10.1128/CMR.17.4.760-769.2004. - DOI - PMC - PubMed
    1. Umbers AJ, Aitken EH, Rogerson SJ. Malaria in pregnancy: small babies, big problem. Trends Parasitol. 2011;27:168–75. doi: 10.1016/j.pt.2011.01.007. - DOI - PubMed
    1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104. doi: 10.1016/S1473-3099(07)70021-X. - DOI - PubMed
    1. Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, et al. The sick placenta-the role of malaria. Placenta. 2004;25:359–78. doi: 10.1016/j.placenta.2003.10.019. - DOI - PubMed
    1. Aitken EH, Mbewe B, Luntamo M, Maleta K, Kulmala T, Friso MJ, et al. Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics and protection during pregnancy in women receiving intermittent preventive treatment. J Infect Dis. 2010;201:1316–25. doi: 10.1086/651578. - DOI - PubMed

Publication types

Associated data